Ticagrelor safety profile in real-life setting of acute coronary syndrome patients

J Chin Med Assoc. 2017 Mar;80(3):183-184. doi: 10.1016/j.jcma.2016.11.003. Epub 2017 Feb 12.

Authors

Niccolò Lombardi¹, Giada Crescioli¹, Ersilia Lucenteforte¹, Alessandro Mugelli¹, Alfredo Vannacci²

Affiliations

¹ Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.
² Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy. Electronic address: alfredo.vannacci@unifi.it.

PMID: 28202337
DOI: 10.1016/j.jcma.2016.11.003

No abstract available

Publication types

Letter
Comment

MeSH terms

Acute Coronary Syndrome*
Adenosine* / analogs & derivatives
Humans
Platelet Aggregation Inhibitors
Ticagrelor
Ticlopidine

Substances

Platelet Aggregation Inhibitors
Ticagrelor
Adenosine
Ticlopidine